Updates on clinical studies of selenium supplementation in radiotherapy

Radiation Oncology

Table 2 Observational studies investigating the selenium levels in patients who underwent radiotherapy without selenium supplementation

Study no.	Reference	Sample	Measurement method	Mean selenium levels (μg/l)
				Before radiotherapy	During radiotherapy		End of radiotherapy	After completion of radiotherapy
1	Pothier et al. [17]	Plasma	AAS	61.8 (at stable stage)	1 week (n = 5)	34.3 ↓	-	-	-
2	Antila et al. [18]	Serum	AAS	130.7*	Middle of therapy	124.4*	128.3*	2 weeks	126.7*
2	Antila et al. [18]	Serum	AAS	130.7*	Middle of therapy	124.4*	128.3*	2 months	121.2*
3	Piccinini et al. [19]	Plasma	Fluorometric method	Breast cancer: 71.81	-	-	-	-	-
3	Piccinini et al. [19]	Plasma	Fluorometric method	Lung cancer:69.59	-	-	-	-	-
4	Rostkowska-Nadolska et al. [20]	Serum	AAS	253.8**	-	-	-	6 weeks	267.5**
5	Yadav et al. [21]	Serum	AAS	62.7	-	-	61.0	1 year	Cured:91.5
5	Yadav et al. [21]	Serum	AAS	62.7	-	-	61.0	1 year	Residual disease: 61.8
6	Last et al. [22]	Serum	ICP-MS	72.44*	-	-	-	-	-
7	Fraunholz et al. [23]	Whole blood	AAS	75.64	-	-	75.88	6 weeks	81.28
8	Franca et al. [24]	Plasma	AAS	≤60 years:101.8	-	-	≤60 years: 58.1↓	-	-
8	Franca et al. [24]	Plasma	AAS	>60 years:65.2	-	-	>60 years: 33.7↓	-	-
9	Zeng YC et al. [25]	Whole blood	AAS	90.4	-	-	56.3↓	-	-’
10	Eroglu C et al. [26]	Serum	ICP-MS	58.09	-	-	56.34	-	-
12	Kiremidjian-Schumacher et al. [28]	Plasma (placebo group)	Graphite-furnace AAS	94.38	-	-	8th weeks: 91.8	8 weeks	89.92
15	Muecke et al. [31]	Whole blood (control group)	AAS	63.2	50% of therapy	67.3	61.4	6 weeks	69

ISSN: 1748-717X